NewAmsterdam Pharma Co N.V. Quarterly Operating Income (Loss) in USD from Q1 2023 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
NewAmsterdam Pharma Co N.V. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2023 to Q2 2024.
  • NewAmsterdam Pharma Co N.V. Operating Income (Loss) for the quarter ending June 30, 2024 was -$52.6M, a 23.8% decline year-over-year.
  • NewAmsterdam Pharma Co N.V. annual Operating Income (Loss) for 2023 was -$183M, a 5044% decline from 2022.
  • NewAmsterdam Pharma Co N.V. annual Operating Income (Loss) for 2022 was -$3.56M, a 89.8% increase from 2021.
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$52.6M -$10.1M -23.8% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-07
Q1 2024 -$55.5M -$15.6M -39.2% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q2 2023 -$42.5M Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-07
Q1 2023 -$39.9M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
* An asterisk sign (*) next to the value indicates that the value is likely invalid.